Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
News Feb 21, 2013
Founded in 1898, Roswell Park Cancer Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and is a member of the prestigious National Comprehensive Cancer Network.
"A key part of our mission at the Center involves research into new therapies, new diagnostic tools and better ways of predicting patient outcomes," said Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine. "The sequencers will be central to this work, quickly generating vast amounts of genomic data that will help us to understand the mechanisms of how cancer develops and spreads."
"The combination of the Ion Proton™ sequencer and the Ion PGM™ sequencer will give the researchers from Roswell Park Cancer Institute a simple workflow from discovery to validation," said Life Technologies President and Chief Operating Officer Mark Stevenson. "Over 1,000 organizations have adopted Ion Torrent technology in the past two years, giving our company more than 60 percent of the desktop sequencer market and reflecting the huge demand for the speed, simplicity and affordability of Ion Torrent technology."
All products referenced are for research use only and not for use in diagnostic procedures.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018